NEW YORK – Start-up Nixxi is developing a mass spectrometry-based test for identifying mothers at high risk of delivering prematurely.
In April, researchers affiliated with the Phoenix, Arizona-based firm published a study in Human Reproduction Open that found that maternal serum levels of 11-deoxycorticosterone (DOC) and 16-alpha-hydroxyprogesterone (16α-OHP) could be used to predict an increased risk delivery prior to 32 weeks.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
